Physicians May Not Be Removing Enough Breast Tissue in Younger Patients

Publication
Article
OncologyONCOLOGY Vol 14 No 4
Volume 14
Issue 4

Younger women who undergo lumpectomy to remove noninvasive breast cancer cells are significantly more likely to experience a recurrence than older patients, in part, because physicians may not be removing enough breast tissue during

Younger women who undergo lumpectomy to remove noninvasive breast cancer cells are significantly more likely to experience a recurrence than older patients, in part, because physicians may not be removing enough breast tissue during surgery, according to a study conducted by researchers at William Beaumont Hospital in Michigan.

Over a 13-year period, lead author Frank Vicini, md, and his research team followed 146 patients who were treated at the Michigan hospital with breast-conserving therapy (lumpectomy plus radiation) for ductal carcinoma in situ (DCIS). They found that younger patients (ie, those under 45 years old) had a significantly greater rate of cancer recurrence (26.1%) than older women (8.6%). This higher rate of recurrence among younger women was due to surgery that may not have “cleared the margins.”

Extent of Surgery, Not Age, Increases Recurrence

When the researchers looked more closely at the 95 patients who had a second lumpectomy due to concerns that some cancerous tissue remained, they found that the 31 younger patients in this group more frequently had less tissue initially removed than the older patients. Thus, the factor most associated with a poor outcome was not age but the extent of the surgery. “Bigger surgeries offered better results,” said Vicini. He speculated that concern for appearance may have been a primary reason for the removal of too little tissue.

However, Vicini stressed that DCIS can present differently in younger patients. “In younger women, cancer can be spread over a slightly larger area in the breast because the tissue is more dense and has more ducts. As women age, ducts are replaced by fat,” he says. “The surgery needs to meticulously clear the margins in both younger and older women.”

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content